Home >> Research Area >>Natural Products>>Miscellaneous>> D-Mannitol busulfan

D-Mannitol busulfan

CAS# 1187-00-4

D-Mannitol busulfan

Catalog No. BCN3789----Order now to get a substantial discount!

Product Name & Size Price Stock
D-Mannitol busulfan: 5mg Please Inquire In Stock
D-Mannitol busulfan: 10mg Please Inquire In Stock
D-Mannitol busulfan: 20mg Please Inquire Please Inquire
D-Mannitol busulfan: 50mg Please Inquire Please Inquire
D-Mannitol busulfan: 100mg Please Inquire Please Inquire
D-Mannitol busulfan: 200mg Please Inquire Please Inquire
D-Mannitol busulfan: 500mg Please Inquire Please Inquire
D-Mannitol busulfan: 1000mg Please Inquire Please Inquire

Quality Control of D-Mannitol busulfan

Number of papers citing our products

Chemical structure

D-Mannitol busulfan

3D structure

Chemical Properties of D-Mannitol busulfan

Cas No. 1187-00-4 SDF Download SDF
PubChem ID 142775 Appearance Powder
Formula C8H18O10S2 M.Wt 338.35
Type of Compound Miscellaneous Storage Desiccate at -20°C
Synonyms Mannitol, 1,6-dimethanesulfonate
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Chemical Name [(2R,3R,4R,5R)-2,3,4,5-tetrahydroxy-6-methylsulfonyloxyhexyl] methanesulfonate
SMILES CS(=O)(=O)OCC(C(C(C(COS(=O)(=O)C)O)O)O)O
Standard InChIKey ODOISJJCWUVNDJ-WCTZXXKLSA-N
Standard InChI InChI=1S/C8H18O10S2/c1-19(13,14)17-3-5(9)7(11)8(12)6(10)4-18-20(2,15)16/h5-12H,3-4H2,1-2H3/t5-,6-,7-,8-/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of D-Mannitol busulfan

The herbs of Peucedanum harry-smithii var. subglabrum

Biological Activity of D-Mannitol busulfan

DescriptionMannitol is a osmotic diuretic, it may play a role in reducing off-target 68Ga-PSMA renal uptake. Mannitol has been used clinically to reduce intracranial pressure with varying success, and it is possible that it is more effective in some types of head injury than in others.
In vivo

Effect of mannitol on cerebral blood flow and cerebral perfusion pressure in human head injury[Pubmed: 3925092 ]

J Neurosurg. 1985 Jul;63(1):43-8.

Patients with severe head injury frequently have evidence of elevated intracranial pressure (ICP) and ischemic neuronal damage at autopsy. Mannitol has been used clinically to reduce ICP with varying success, and it is possible that it is more effective in some types of head injury than in others.
METHODS AND RESULTS:
The aim of the present study was to determine the effect of Mannitol on ICP, cerebral perfusion pressure (CPP), and cerebral blood flow (CBF) in patients with severe head injury, and to discover if these effects differed in different types of injury. Measurements of CPP, ICP, and CBF were made in 55 patients with severe head injury. In general, the resting level of CBF was higher in patients with diffuse injury (mean 50.2 ml/100 gm/min) than in those with focal injury (mean 39.8 ml/100 gm/min). Mannitol consistently reduced ICP and increased CPP and CBF by 10 to 20 minutes after infusion. The lowest flows (31.8 ml/100 gm/min) were recorded from the most damaged hemispheres of patients with focal injuries and elevated ICP. The baseline levels of flow did not correlate with ICP, CPP, Glasgow Coma Scale score, or outcome. Only four of the 55 patients had a CBF of less than 20 ml/100 gm/min in either or both hemispheres.
CONCLUSIONS:
The few low CBF's in this and other studies may reflect the steady-state conditions under which measurements are made in intensive care units, and that these patients have entered a phase of reperfusion.

Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results.[Pubmed: 28801787]

Eur J Nucl Med Mol Imaging. 2017 Aug 11.

Urea-based prostate-specific membrane antigen (PSMA) ligands labelled with 68Ga or 177Lu are new tracers with great potential for theranostic approaches in prostate cancer. However, clinical studies have shown that the kidneys are one of the off-target organs along with the salivary and lacrimal glands. In the kidneys, PSMA is physiologically expressed in the apical epithelium of the proximal tubules, and Mannitol acts as an osmotic diuretic in these tubules.
METHODS AND RESULTS:
We investigated the potential of Mannitol to reduce renal uptake of 68Ga-PSMA. Kidney uptake (SUVmax) was calculated in nine patients undergoing 68Ga-PSMA PET/CT at baseline (b-PET/CT) and after intravenous infusion of 500 ml of 10% Mannitol (m-PET/CT). Two different infusion schemes for Mannitol were used: (1) 500 ml Mannitol was infused over 40 min after 68Ga-PSMA administration (A-infusion) and (2) 250 ml Mannitol was infused over 15 min before and again after 68Ga-PSMA administration (B-infusion). In patients receiving the A-infusion, mean SUVmax increased by 11.9% and 7.4% in the right and left kidney, respectively. In patients receiving the B-infusion, mean SUVmax decreased by 24.3% and 22.4% in the right and left kidney, respectively. Our preliminary findings indicate that Mannitol may play a role in reducing off-target 68Ga-PSMA renal uptake. Administration of the osmotic diuretic should be rapid and start before 68Ga-PSMA injection.
CONCLUSIONS:
These results warrant dosimetric studies in patients treated with 177Lu-PSMA to find the best scheme for Mannitol administration.

D-Mannitol busulfan Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

D-Mannitol busulfan Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of D-Mannitol busulfan

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.9555 mL 14.7776 mL 29.5552 mL 59.1104 mL 73.888 mL
5 mM 0.5911 mL 2.9555 mL 5.911 mL 11.8221 mL 14.7776 mL
10 mM 0.2956 mL 1.4778 mL 2.9555 mL 5.911 mL 7.3888 mL
50 mM 0.0591 mL 0.2956 mL 0.5911 mL 1.1822 mL 1.4778 mL
100 mM 0.0296 mL 0.1478 mL 0.2956 mL 0.5911 mL 0.7389 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on D-Mannitol busulfan

Reduction of (68)Ga-PSMA renal uptake with mannitol infusion: preliminary results.[Pubmed:28801787]

Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2189-2194.

PURPOSE: Urea-based prostate-specific membrane antigen (PSMA) ligands labelled with (68)Ga or (177)Lu are new tracers with great potential for theranostic approaches in prostate cancer. However, clinical studies have shown that the kidneys are one of the off-target organs along with the salivary and lacrimal glands. In the kidneys, PSMA is physiologically expressed in the apical epithelium of the proximal tubules, and mannitol acts as an osmotic diuretic in these tubules. We investigated the potential of mannitol to reduce renal uptake of (68)Ga-PSMA. METHODS: Kidney uptake (SUVmax) was calculated in nine patients undergoing (68)Ga-PSMA PET/CT at baseline (b-PET/CT) and after intravenous infusion of 500 ml of 10% mannitol (m-PET/CT). Two different infusion schemes for mannitol were used: (1) 500 ml mannitol was infused over 40 min after (68)Ga-PSMA administration (A-infusion) and (2) 250 ml mannitol was infused over 15 min before and again after (68)Ga-PSMA administration (B-infusion). RESULTS: In patients receiving the A-infusion, mean SUVmax increased by 11.9% and 7.4% in the right and left kidney, respectively. In patients receiving the B-infusion, mean SUVmax decreased by 24.3% and 22.4% in the right and left kidney, respectively. CONCLUSION: Our preliminary findings indicate that mannitol may play a role in reducing off-target (68)Ga-PSMA renal uptake. Administration of the osmotic diuretic should be rapid and start before (68)Ga-PSMA injection. These results warrant dosimetric studies in patients treated with (177)Lu-PSMA to find the best scheme for mannitol administration.

Effect of mannitol on cerebral blood flow and cerebral perfusion pressure in human head injury.[Pubmed:3925092]

J Neurosurg. 1985 Jul;63(1):43-8.

Patients with severe head injury frequently have evidence of elevated intracranial pressure (ICP) and ischemic neuronal damage at autopsy. Mannitol has been used clinically to reduce ICP with varying success, and it is possible that it is more effective in some types of head injury than in others. The aim of the present study was to determine the effect of mannitol on ICP, cerebral perfusion pressure (CPP), and cerebral blood flow (CBF) in patients with severe head injury, and to discover if these effects differed in different types of injury. Measurements of CPP, ICP, and CBF were made in 55 patients with severe head injury. In general, the resting level of CBF was higher in patients with diffuse injury (mean 50.2 ml/100 gm/min) than in those with focal injury (mean 39.8 ml/100 gm/min). Mannitol consistently reduced ICP and increased CPP and CBF by 10 to 20 minutes after infusion. The lowest flows (31.8 ml/100 gm/min) were recorded from the most damaged hemispheres of patients with focal injuries and elevated ICP. The baseline levels of flow did not correlate with ICP, CPP, Glasgow Coma Scale score, or outcome. Only four of the 55 patients had a CBF of less than 20 ml/100 gm/min in either or both hemispheres. The few low CBF's in this and other studies may reflect the steady-state conditions under which measurements are made in intensive care units, and that these patients have entered a phase of reperfusion.

Keywords:

D-Mannitol busulfan,1187-00-4,Mannitol, 1,6-dimethanesulfonate,Natural Products, buy D-Mannitol busulfan , D-Mannitol busulfan supplier , purchase D-Mannitol busulfan , D-Mannitol busulfan cost , D-Mannitol busulfan manufacturer , order D-Mannitol busulfan , high purity D-Mannitol busulfan

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: